ABBOTT PARK, Ill. and MILPITAS, Calif., – Abbott Laboratories and Bigfoot Biomedical will collaborate to develop and commercialize diabetes management systems, integrating Abbott’s FreeStyle Libre glucose sensing technology with Bigfoot’s insulin delivery solutions. “Together with Bigfoot, we are challenging conventional methods of diabetes management by bringing together our expertise in superior glucose monitoring technology with a best-in-class insulin delivery system that is designed with the patient in mind,” said Jared Watkin, senior vice president of Diabetes Care at Abbott, in a statement. As part of the agreement, Abbott will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology, which Bigfoot will use to develop personalized, user-friendly systems intended to optimize insulin delivery without the need for fingerstick calibration of a glucose sensor. “A no-calibration glucose sensor is the final piece of the puzzle needed to enable consumer-friendly and accessible integrated insulin delivery systems,” said Jeffrey Brewer, president and CEO of Bigfoot Biomedical, in a statement.
You are here: / / Abbott, Bigfoot Biomedical develop calibration-free insulin delivery system